EUVIMEDAtrasti EUVIMED
Übersichtsarbeit

The clinical terrain of immunotherapies in heterogeneous pancreatic cancer: unravelling challenges and opportunities

Melanie Herpels iD, Jun Ishihara, Anguraj Sadanandam iD

The Journal of Pathology · 2023

DOI: 10.1002/path.6171 ↗

At a glance

Übersichtsarbeit in The Journal of Pathology, 2023. Written by Melanie Herpels and 2 co-authors. Institution: Division of Molecular Pathology, Institute of Cancer Research, London, UK. Major MEDLINE topics: Pancreatic Neoplasms, Carcinoma, Pancreatic Ductal. Cited 10 times so far (Crossref); 168 references.

SantraukaSubjectsBibliografiniai duomenysCiteRelated studies

Abstract (original language)

Pancreatic ductal adenocarcinoma (PDAC) is the most common and aggressive type of pancreatic cancer and has abysmal survival rates. In the past two decades, immunotherapeutic agents with success in other cancer types have gradually been trialled against PDACs at different stages of cancer progression, either as a monotherapy or in combination with chemotherapy. Unfortunately, to this day, chemotherapy still prolongs the survival rates the most and is prescribed in clinics despite the severe side effects in other cancer types. The low success rates of immunotherapy against PDAC have been attributed most frequently to its complex and multi‐faceted tumour microenvironment (TME) and low mutational burden. In this review, we give a comprehensive overview of the immunotherapies tested in PDAC clinical trials thus far, their limitations, and potential explanations for their failure. We also discuss the existing classification of heterogenous PDACs into cancer, cancer‐associated fibroblast, and immune subtypes and their potential opportunity in patient selection as a form of personalisation of PDAC immunotherapy. © 2023 The Pathological Society of Great Britain and Ireland.

Subjects

MeSH terms (MEDLINE)

Pancreatic NeoplasmsCarcinoma, Pancreatic DuctalHumansImmunotherapyUnited KingdomTumor Microenvironment

Author keywords

cancer-associated fibroblastsclinical trialsimmune checkpoint inhibitorsimmunotherapyimmunotherapy failurepancreatic cancersubtypestumour microenvironment

Authors and institutions

  • Division of Molecular Pathology, Institute of Cancer Research, London, UK.
  • Department of Bioengineering, Imperial College London, London, UK.
  • Centre for Global Oncology, Division of Molecular Pathology, Institute of Cancer Research, London, UK.
  • Centre for Translational Immunotherapy, Division of Radiotherapy and Imaging, Institute of Cancer Research, London, UK.

ORCID profiles: Melanie Herpels, Anguraj Sadanandam

Cite

APA

Herpels, M., Ishihara, J., & Sadanandam, A. (2023). The clinical terrain of immunotherapies in heterogeneous pancreatic cancer: unravelling challenges and opportunities. The Journal of Pathology. https://doi.org/10.1002/path.6171

Vancouver

Herpels M, Ishihara J, Sadanandam A. The clinical terrain of immunotherapies in heterogeneous pancreatic cancer: unravelling challenges and opportunities. The Journal of Pathology. 2023. doi:10.1002/path.6171

BibTeX
@article{Herpels2023,
  author = {Herpels, Melanie and Ishihara, Jun and Sadanandam, Anguraj},
  title = {The clinical terrain of immunotherapies in heterogeneous pancreatic cancer: unravelling challenges and opportunities},
  journal = {The Journal of Pathology},
  year = {2023},
  doi = {10.1002/path.6171}
}
Start for free →